title: Mutating His29, His125, His133 or His158 abolishes glycosylphosphatidylinositol-specific phospholipase D catalytic activity.
abstract: Glycosylphosphatidylinositol (GPI)-specific phospholipase D (GPI-PLD) specifically cleaves GPIs. This phospholipase D is a secreted protein consisting of two domains: an N-terminal catalytic domain and a predicted C-terminal b-propeller. Although the biochemical properties of GPI-PLD have been extensively studied, its catalytic site has not been identified. We hypothesized that a histidine residue(s) may play a critical role in the catalytic activity of GPI-PLD, based on the observations that (i) Zn2+, which utilizes histidine residues for binding, is required for GPI-PLD catalytic activity, (ii) a phosphohistidine intermediate is involved in phospholipase D hydrolysis of phosphatidylcholine, (iii) computer modelling suggests a catalytic site containing histidine residues, and (iv) our observation that diethyl pyrocarbonate, which modifies histidine residues, inhibits GPI-PLD catalytic activity. Individual mutation of the ten histidine residues to asparagine in the catalytic domain of murine GPI-PLD resulted in three general phenotypes: not secreted or retained (His56 or His88), secreted with catalytic activity (His34, His81, His98 or His219) and secreted without catalytic activity (His29, His125, His133 or His158). Changing His133 but not His29, His125 or His158 to Cys resulted in a mutant that retained catalytic activity, suggesting that at least His133 is involved in Zn2+ binding. His133 and His158 also retained the biochemical properties of wild-type GPI-PLD including trypsin cleavage pattern and phosphorylation by protein kinase A. Hence, His29, His125, His133 and His158 are required for GPI-PLD catalytic activity.
authors.affiliation: Department of Medicine, Indiana University School of Medicine and the Department of Veterans Affairs, Richard L. Roudebush VAMC, Indianapolis, IN 46202, USA.
authors.forename: Nandita S
authors.initials: NS
authors.lastname: Raikwar
authors.forename: Rosario F
authors.initials: RF
authors.lastname: Bowen
authors.forename: Mark A
authors.initials: MA
authors.lastname: Deeg
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics*; D000818:Animals; D002384:Catalysis; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D017261:Glycosylphosphatidylinositols / Q000378:metabolism*; D006639:Histidine / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D051379:Mice; D009154:Mutation / Q000235:genetics; D010739:Phospholipase D / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*; D010766:Phosphorylation; D017434:Protein Structure, Tertiary; D013379:Substrate Specificity; D014357:Trypsin / Q000378:metabolism
chemical_list: D017261:Glycosylphosphatidylinositols; D006639:Histidine; D017868:Cyclic AMP-Dependent Protein Kinases; D010739:Phospholipase D; D014357:Trypsin